CATEGORIES: CMT Update

Amazing Opportunity: AntiGravity Exercise Study in New York City!

by | Jul 31, 2017 | 4 comments

Estela AlterG

HNF is excited to announce a new avenue of research for improving the physical and emotional well-being of individuals living with CMT. Beginning this summer and continuing through the coming year, we will be funding and conducting an exclusive research study for people with CMT featuring the AlterG anti-gravity treadmill in New York City!

CALL 212-600-4781 TO LEARN MORE AND TO ENROLL!

This incredible new technology allows patients to stand, walk, and be supported as needed to improve balance, gain endurance, and reach greater speed, all without the risk of falling! This innovative machine—which was designed by NASA—features an airtight casing and powerful series of fans. Patients are zipped in and are able to reduce their body weight and the effects of gravity down to 20%.

This new combination of “weightlessness” and support was enough to allow Estela Lugo, a patient with CMT, to run for the first time in her adult life. “I lost all movement from the knee down before the age of 10 and have been wearing AFO’s since kindergarten. I didn’t think I would ever experience running in my lifetime. I stepped into this machine and was running within a few minutes. There aren’t any words to completely describe how amazing that felt.” One year and 116 miles later, Estela is displaying encouraging results and is more determined than ever to bring this technology to the CMT community. “We believe that movement is medicine and can greatly improve quality of life. The AlterG gets patients moving in new ways and pushes the boundaries of disability.” We are hopeful that bringing the AlterG and more mobility activities to patients with CMT will help to improve independence and quality of life for the community. 

Dr. James Nussbaum, PT, PhD, SCS, EMT, physical therapist and research and clinical director of ProHealth & Fitness PT OT in Manhattan, is an expert in the rehabilitation of patients with CMT. He has been treating patients with CMT and other neuromuscular diseases for more than 15 years, and has presented his research throughout the US and abroad. Dr. Nussbaum is leading our AlterG exercise study in New York city, and the enrollment is currently open. Interested patients or family members should call 212.600.4781 and ask about the AlterG CMT study.

Study participants will have a diagnosis of CMT, and will come in for an extensive initial evaluation, and then will do 30 minute exercise sessions three times a week for three months. Patient will be re-evaluated at the conclusion of the study and then again three and nine months later to assess changes in balance, mobility, and quality of life.

Study participants will participate free of charge, and will agree to partake in the thrice weekly sessions and the assessments of the study. Patients of all abilities are eligible to be evaluated: those with and without braces, with and without assistive devices (canes, walkers, etc.) may be eligible.

TAKE THIS AMAZING OPPORTUNITY TO BENEFIT FROM THE CUTTING EDGE OF RESEARCH IN CMT, CALL TODAY! 212.600.4781 AND ASK ABOUT THE ALTERG CMT STUDY.

WWW.PROHEALTHPTOT.COM

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Taking Matters Into Your Own Hands

Do you have a rare form of CMT?

We were contacted recently from a patient with CMT2D who was looking for advice on how to make a difference. Our recommendations for all people with an ultra-rare form of CMT who want to get involved:

Now GRIN is Accessible in 141 Different Languages!

Now GRIN is Accessible in 141 Different Languages!

The Global Registry for Inherited Neuropathies (GRIN) has implemented Google Translate. Why did we choose Google? Because Google is leading the way in teaching computers how to interpret meaning, avoiding the traditional method of decoding language.

Accelerating Patient Access to Investigational Drugs in 2015

Accelerating Patient Access to Investigational Drugs in 2015

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched.

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Join the conversation

Leave a Comment

4 Comments

  1. Allison Moore

    Hi Collin, if the study shows benefits for patients with CMT, HNF will consider expanding a study globally contingent on funding. Thank you for your interest.

    Reply
  2. Collin Stoll

    I am in Portland Oregon and would very much like to participate if a branch study was set up here. I think Nike has an AlterG but not sure about OHSU.

    Reply
  3. Alllison Moore

    Hi Lesley, can you please share the name of the facility in Phoenix that has the AlterG. We will add them to our AlterG Directory and I would reach out to them. Have you done the AlterG? Do they specialize in CMT patient care? Allison Moore, HNF

    Reply
  4. Lesley Fry

    I wish I could participate. There is one 2 miles from my home near Phoenix.

    Reply

Leave a Reply to Collin Stoll Cancel reply

Your email address will not be published. Required fields are marked *

Newsletter

Join for notifications on events, campaigns, & news